An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...
Saved in:
Main Authors: | Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. vanEsdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van derPluijm, Jacobus Burggraaf, Susanne Osanto |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7f6f12eb65c74ad0b8cee9f1481033da |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
by: Nikolai A. Ognerubov
Published: (2021) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
by: Faiza Naseer, et al.
Published: (2021) -
TRACING THE CRIMINAL POLICY ON CASTRATION AND COMMUNITY RESPONSE
by: Mompang L Panggabean
Published: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
by: Archibald M, et al.
Published: (2016)